Delaware |
000-19125 |
33-0336973 |
(State or Other Jurisdiction of Incorporation) |
(Commission File No.)
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
| ||
Common Stock, $.001 Par Value |
"IONS" |
The Nasdaq Stock Market, LLC |
Emerging growth company
|
☐ |
Item 1.01 |
Entry into a Material Definitive Agreement.
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Full Year 2022 Guidance
|
Revised
Guidance
|
Previous As of
Q3 2022
|
Revenue
|
>$575 million
|
>$575 million
|
Operating expenses on a non-GAAP basis
|
$900-$925 million
|
$825-$850 million
|
Net loss on a non-GAAP basis
| <$350 million
| <$275 million
|
Cash, cash equivalents and short-term investments
|
~2.0 billion
|
~$2.0 billion
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit No. |
Description |
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
Ionis Pharmaceuticals, Inc.
| ||
Dated: November 14, 2022
|
By:
|
/s/ Patrick R. O'Neil
|
Patrick R. O'Neil
| ||
Executive Vice President, Chief Legal Officer and General Counsel
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ionis Pharmaceuticals Inc. published this content on 14 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 November 2022 11:33:09 UTC.